Pfizer (PFE) Cash & Equivalents (2009 - 2026)

Pfizer has disclosed Cash & Equivalents across 18 years of filings, most recently posting $1.7 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 19.09% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 19.09% YoY), while the FY2025 annual figure was $1.1 billion, up 9.49% from the prior year.
• Cash & Equivalents climbed to $1.7 billion in Q1 2026, from $1.1 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for PFE reached as high as $3.1 billion in Q4 2023 and fell as low as $416.0 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $1.4 billion (2025), against an average of $1.6 billion.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 78.6% — and 2023, when it jumped 585.82%.
• A 5-year view of Cash & Equivalents shows it stood at $416.0 million in 2022, then jumped by 585.82% to $2.9 billion in 2023, then plunged by 63.44% to $1.0 billion in 2024, then rose by 9.49% to $1.1 billion in 2025, then soared by 49.12% to $1.7 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.7 billion, $1.1 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.